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We aimed to characterise the population pharmacokinetics of cholesteryl ester
transferase protein inhibitor DRL-17822 in healthy males and explore the effect
of food and formulation on the oral absorption of DRL-17822 in 4 phase I studies.
DRL-17822 was dosed orally (2–1000 mg) in 2 different drug formulations (nano-
crystal formulation and amorphous solid dispersion formulation) after either an
overnight fast, or a low-fat, continental or high-fat breakfast. A 2-compartment
model with 6 transit absorption compartments best characterised the data. Addi-
tionally, a strong interaction of food and formulation on bioavailability was
observed and parsimoniously characterised in the model by binning combinations
of food state and formulation with similar bio-availabilities. The final model ade-
quately characterised the pharmacokinetic data of DRL-17822 in healthy males
including the complex interaction of food and drug formulation. The amorphous
solid dispersion formulation has a lower food effect on bioavailability compared
with the nanocrystal formulation.
K E YWORD S
cardiovascular, cholesteryl ester transferase protein inhibitor, food/drug interaction,
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1 | INTRODUCTION
The levels of high-density lipoprotein (HDL)-cholesterol are an inverse
predictor for the risk of atherosclerotic cardiovascular disease.1 It was
therefore proposed that increase in HDL-cholesterol levels may be
beneficial in the treatment of cardiovascular disease.2 An effective
method to increase plasma HDL-cholesterol is the inhibition of
cholesteryl ester transferase protein (CETP), which promotes the
transfer of cholesteryl esters from HDL to low-density lipoproteins
(LDL) and very-low-density lipoproteins.3 In addition to the HDL
increasing effect, CETP inhibitors have been shown to reduce levels
of LDL-cholesterol.4
DRL-17822 is a strongly lipophilic (logP = 8.86) CETP inhibitor
currently in clinical development, which has been well tolerated in
healthy volunteers in single doses (2–1000 mg) and once daily dosing
for 2 weeks (50–450 mg).5,6 In the multiple dose study in healthy
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volunteers, DRL-17822 increased levels of HDL-cholesterol (51– to
111%), and reduced levels of LDL-cholesterol (−25 to −56%).
During the phase I studies, large differences in exposure were
observed when the nanocrystal formulation of DRL-17822 was
administered orally after an overnight fast vs a standard high-fat or
continental breakfast.7 An amorphous solid dispersion oral formula-
tion of DRL-17822 was therefore developed to reduce the effect of
food, and compared with the nanocrystal formulation in a randomised
open-label, 4-way cross-over trial.7
The wide range of tested doses combined with the complex inter-
action of food and drug formulation complicated the interpretation of
the phase I pharmacokinetic (PK) data. Therefore, in this study, we
used population PK modelling to analyse the data from all phase I
studies of DRL-17822 in an integrated manner, so that the resulting
model may support future studies.
2 | METHODS
2.1 | Clinical studies
Data from 4 phase I studies were analysed, which were all conducted
according to the principles of the Declaration of Helsinki and the
European guidelines on Good Clinical Practice. All subjects provided
written informed consent, prior to study enrolment. Studies 1, 2 and
3 were approved by the independent Medical review and Ethics Com-
mittee STEG/METC (The Netherlands). Study 4 was approved by
independent Medical Review and Ethics Committee BEBO (The Neth-
erlands). All studies were performed under sponsor responsibility of
Dr Reddy's Laboratories, which provided the quality controlled raw
data. Study 1 was the first-in-human single-dose phase I study, Study
2 was a single-dose food interaction study, Study 3 was a 2-week
once-daily multiple-dose study, and Study 4 (parts A and B) was a
single-dose food and formulation interaction study. In all studies,
DRL-17822 concentrations were measured using validated liquid
chromatography–tandem mass spectrometry methods.7 Analyses
were performed in compliance with Good Laboratory Practice regula-
tions. Subject demographics by study are shown in Table S1, and
show no large differences between the populations. Table S2 gives an
overview of the 4 studies included in this analysis, including the doses,
formulations and food intake before dosing in each study.5–7
2.2 | PK model development
Model development was performed in NONMEM version 7.2 using a
first-order conditional estimation with interaction method.8 Data
below the limit of quantitation were excluded (8.4% of total data
points).9 A systematic, stepwise approach was used to develop the
model. First, 2- and 3-compartment models were explored with vari-
ous absorption submodels: (i) first-order absorption; (ii) first-order
absorption with absorption lag time and (iii) first-order absorption
through a series of empirical transit compartments (models with
increasing number of transit compartments were tested). The effect
of food and formulation on relative bioavailability was modelled by
pooling the 7 possible combinations of food before dose and formula-
tion in an optimal number of bins. The bioavailability was
parameterised as relative to the food+formulation bin with the highest
bioavailability (Freference, fixed to 1.0). The base model started with
2 bins, 1 for all fasted doses and 1 for all doses after food. Both inter-
individual (IIV) and interoccasion (IOV) variability were assumed to be
log-normally distributed. The use of additive, proportional and com-
bined residual error models were explored. Covariates (age, body
weight, height and body mass index [BMI] that showed a Pearson's
correlation (R2 > 0.5) with the individual posthoc parameter estimates
were formally tested during model development using a forward inclu-
sion (P < .05) and backwards elimination (P < .01) procedure. Nested
models were compared with the likelihood ratio test to determine
whether the more complex model resulted in a significant (P < .05)
improvement in model fit.
2.3 | Model evaluation
Models were assessed based on the relative standard error (RSE) of
parameter estimates and several diagnostic plots: (i) observed and
predicted concentrations vs time; (ii) observed concentrations vs pop-
ulation predicted concentration (PRED); (iii) observed concentrations
vs individual predicted concentrations (IPRED); (iv) conditional
What is already known about the subject
• DRL-17822 is a novel cholesteryl ester transferase pro-
tein inhibitor, currently in clinical development.
• DRL-17822 is well tolerated and increases high-density
lipoprotein-cholesterol levels, while decreasing low-
density lipoprotein-cholesterol levels.
• Like several other cholesteryl ester transferase protein
inhibitors, DRL-17822's oral absorption is influenced by
food intake.
What this study adds
• A 2-compartment model with transit compartment
absorption adequately characterises the pharmacokinet-
ics of DRL-17822 in healthy males.
• Quantified the complex interaction of food and formula-
tion on the oral absorption (rate and extent) of DRL-
17822 using modelling.
• An oral amorphous solid dispersion formulation of DRL-
17822 showed a lower food effect on bioavailability,
compared with the nanocrystal formulation.
2 GOULOOZE ET AL.
weighted residuals with interaction (CWRESI) vs PRED; and
(v) CWRESI vs time.10,11 A prediction-corrected visual predictive
check (VPC) was performed to evaluate potential misspecification in
the final model.12
2.4 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY.
3 | RESULTS
3.1 | PK model description
A total of 2816 DRL-17822 plasma concentrations in 95 subjects
were available for analysis. After a stepwise development (Table S3),
the final PK model for DRL-17822 is parameterised in terms of rela-
tive bioavailability (F), absorption rate constant (ka), apparent volume
of the central compartment (Vc), apparent volume of the peripheral
compartment (Vp), intercompartmental clearance (Qc/p) and first-order
elimination rate constant (kel). Parameter estimates are reported in
Table 1, and final model code can be found in the Supplemental Mate-
rial. A 3-compartment model did not improve the model fit and
resulted in overparameterisation of the model and was thus not taken
forward in the model development. An empirical absorption model
with 6 transit compartments between the dosing and central compart-
ment was used, as it resulted in the lowest Akaike information crite-
rion among the tested absorption models.
The best PK model for DRL-17822 consisted of 4 bins to charac-
terise the interaction of food and formulation on relative bioavailabil-
ity (Freference, Fmedium, Fmedium-low, Flow). Adding a fifth bin did not
result in improved model fit. This resulted in Freference (F = 1) being
represented by the nanocrystal formulation after a high-fat or conti-
nental breakfast. Fmedium represents the relative bioavailability (rela-
tive to Freference) of the amorphous solid dispersion formulation after a
low- or high-fat breakfast and the nanocrystal formulation after a
low-fat breakfast. Fmedium-low represents the relative bioavailability of
the amorphous solid dispersion formulation in fasted state. The lowest
relative bioavailability, Flow represents the nanocrystal formulation in
fasted state.
For the nanocrystal formulation of DRL-17822, a high-fat or
continental breakfast before drug administration results in an 18-fold
increase in bioavailability (Freference), compared with a fasted state
(Flow). This food effect appears to be dependent on the type of
breakfast, as the bioavailability after a low-fat breakfast is 2-fold
lower (Fmedium) than after a high-fat or continental breakfast. The
amorphous solid dispersion formulation lowers the food effect on
bioavailability, for which the difference between fasted (Fmedium-low)
and high-fat breakfast (Fmedium) dosing is 3.5-fold. Additionally, no
difference in bioavailability of the amorphous solid dispersion formu-
lation could be identified between a high-fat and low-fat breakfast
(both in Fmedium-bin).
A significantly lower ka was identified for the amorphous solid
dispersion formulation of DRL-17822 after a high-fat breakfast
TABLE 1 Parameter estimates and uncertainties of pharmacokinetic model
Parameter Estimate [RSE%] IIV (CV%)a [RSE%] IOV (CV%) [RSE%]
ka (h
−1) 1.74 [2.5] 25.4 [16.3] 20.9 [16.2]
Vc (L) 86.7 [6.7] 26.7 [27.8]
kel (h
−1) 0.100 [3.1] 23.8 [26.4]
Vp (L) 599 [6.7]
Qc/p (L/h) 5.11 [6.3]
Freference 1.0 [fixed] 69.2 [27.6] 44.8 [13.7]
Fmedium 0.532 [3.2] As Freference As Freference
Fmedium-low 0.151 [10.7] As Freference As Freference
Flow 0.056 [8.7] As Freference As Freference
COVBMI, Vc 0.041 [16.3]
ka,asd,HF 0.599 [11.2]
Cor. IIV Vc-ka 0.707 [28.7]
Cor. IIV F-ka −0.280 [35.7]
Cor. IOV F-ka −0.089 [36.4]
Proportional error (σ2) 0.114 [4.8]





COVBMI, VC, covariate effect of BMI on Vc; Cor., correlation; HF, high-fat; IIV, interindividual variability; IOV, interoccasion variability; ka,asd,HF, fraction of ka
for the amorphous solid dispersion formulation after a high-fat breakfast; RSE, relative standard error.
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F IGURE 1 Goodness-of-fit plots. Line of unity (straight grey line) and a LOESS smoother curves (dashed black line) are shown to aid
interpretation. The conditional weighted residuals (CWRESI) over time plot is shown separately for the single dose studies (studies 1, 2 and 4) and
the multiple dose study (study 3). The lower limit of quantification of the pharmacokinetic assay ranged from 0.1 to 20 ng/mL among the
different studies (see Table S2 for more details)
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F IGURE 2 Prediction-corrected visual predictive check (1000 samples) of the single (A) and multiple dose (B) studies using the final
parameter estimates (Table 1). Observations are shown as solid circles. The median of the binned observations is shown as a red solid line, while
the 5 and 95% percentiles are shown as a blue solid line. The 90% confidence interval of the simulated median, and the 5 and 95% percentile are
depicted with red and blue shaded rectangles
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(difference in objective function value, ΔOFV = −62.04, P < 10−14),
parameterised as fraction of the population ka (ka,asd,HF). The same
degree of IIV and IOV of ka was estimated for all food
+formulation bins.
IIV was identified for F, ka, Vc and kel. IOV on F and ka signifi-
cantly improved the individual fit of the data and was therefore
included in the model. Individual BMI explained part of the IIV of the
Vc (ΔOFV = −12.23, P < .001), and was therefore included in the final
model. Correlations were identified between 3 pairs of variability:
(i) IIV of Vc and ka; (ii) IIV of F and ka; (iii) IOV of F and ka.
3.2 | PK model evaluation
The goodness-of-fit was graphically assessed (Figure 1). Above the
lowest lower limit of quantification (0.1 ng/mL), there is no clear bias
in plots of the population or individual predictions vs the observations.
Some time-dependent bias can be observed in the CWRESI of the
single-dose studies (underprediction of concentrations at
24–48 hours after dose). This bias is largely absent in the multiple
dose study, although there appears to be an underprediction of DRL-
17822 concentrations at 3 weeks after the last dose. A minor bias
was observed in the CWRESI of population predictions below
0.1 ng/mL (the limit of quantification of Study 1). The prediction-
corrected VPC (Figure 2) indicates that the data are, overall, well
characterised by the model. However, just like the CWRESI over time
plot, there is some bias towards underprediction of concentrations in
the single dose studies between 24–48 hours after dose. Additionally,
the observed 95% percentile is below the 90% confidence interval of
the simulated 95% percentile in several of the bins in the multiple
dose study (Figure 2b). The observed 5% percentile is above the 90%
confidence interval of the simulated 5% percentile in most of the bins
of the single dose study (Figure 2a).
4 | DISCUSSION
The population pharmacokinetics of DRL-17822 were best
characterised with a 2-compartment model, and with 6 transit com-
partments to empirically describe the complex time-course of oral
absorption. Additionally, we quantified the interaction of food and
formulation on the pharmacokinetics of DRL-17822, a poorly soluble,
highly lipophilic CETP inhibitor. While both formulations show an
influence of food or fat content on the bioavailability of DRL-17822,
this effect is larger in the nanocrystal formulation than with the amor-
phous solid dispersion formulation. This reduced impact of food on
the absorption of the amorphous solid dispersion has been suggested
to originate from the solubility-enhancing effect of the water-
insoluble polymers in this formulation.7
We identified BMI as a covariate on the Vc, with an estimated
4.1% increase in Vc per point increase BMI, which might be explained
by high lipophilicity of DRL-17822. Future studies should assess
whether the DRL-17822 pharmacokinetics are similar for subjects
with BMI values above 30 kg/m2, women and patients, as only
healthy male volunteers with BMI values between 18.8–29.9 kg/m2
were included in this study.
The diagnostics (Figures 1 and 2) reveal some misspecifications of
the model that could not be resolved during model development,
especially in single dose studies after 24 hours or more after dose.
However, the multiple-dose data are better characterised, and since
DRl-17822 is expected to be chronically dosed once daily, the model
is likely fit-for-purpose. In the prediction-corrected VPC, there is over-
prediction of the 95% percentile of the multiple dose study (Figure 2).
This suggests that the IIV of DRL-17822's bioavailability did not per-
fectly follow a log-normal distribution. However, the use of semi-
parametric distribution with estimated shape parameters did not solve
this issue.13 The limitations of the model should be taken into account
when using the model for simulations.
Although research on the therapeutic window of DRL-17822 in
patient populations is ongoing, the effect of food on oral absorption
can have potential impact on the compounds effect and safety in the
patient population. For further clinical studies with DRL-17822, the
selection of drug intake instructions (with or without food) might be
just as important as the dose. The timing of the dose (morning or at
night) could also affect patient compliance with these instructions,
depending on their usual breakfast routine. Patient compliance with
drug intake instructions will be likely to affect DRL-17822 exposure,
and possibly also its safety and efficacy profile. The reduced food
effect of the amorphous solid dispersion is therefore a beneficial trait.
In conclusion, we developed a population PK model for DRL-
17822, a novel CETP inhibitor. The model adequately characterises
the pharmacokinetics of DRL-17822 and quantifies the impact of a
potentially clinically significant interaction between food and oral drug
formulation on absorption. The model can serve as a starting point for
a PK model in the patient population or for PK-PD models. Addition-
ally, simulations with the model can guide design of future clinical tri-
als. The impact of patient compliance with drug intake instructions—
which could be relevant for clinical outcomes due to the strong food
effect—should also be considered in such simulations.
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